Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors

被引：39

作者：

Sequist, Lecia V. ^{[1
]}

Cassier, Phillippe ^{[2
]}

Varga, Andrea ^{[3
]}

Tabernero, Josep ^{[4
]}

Schellens, Jan H. ^{[5
]}

Delord, Jean-Pierre ^{[6
]}

LoRusso, Patricia ^{[7
]}

Camidge, D. Ross ^{[8
]}

Hidalgo Medina, Manuel ^{[9
]}

Schuler, Martin ^{[10
]}

Campone, Mario ^{[11
]}

Tian, G. Gary ^{[12
]}

Wong, Steven ^{[13
]}

Corral, Jesus ^{[14
]}

Isaacs, Randi ^{[15
]}

Sen, Suman K. ^{[16
]}

Porta, Diana Graus ^{[17
]}

Kulkarni, Swarupa G. ^{[16
]}

Lefebvre, Caroline ^{[18
]}

Wolf, Juergen ^{[19
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Ctr Leon Berard, F-69373 Lyon, France

[3] Inst Gustave Roussy, Villejuif, France

[4] Vall dHebron Univ Hosp, Barcelona, Spain

[5] Netherlands Canc Inst, Amsterdam, Netherlands

[6] Inst Claudius Regaud, Toulouse, France

[7] Karmanos Canc Inst, Detroit, MI USA

[8] Univ Colorado, Aurora, CO USA

[9] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain

[10] Univ Duisburg Essen, West German Canc Ctr, Essen, Germany

[11] Ctr Rene Gauducheau, F-44035 Nantes, France

[12] West Clin, Memphis, TN USA

[13] UCLA Med Ctr, Los Angeles, CA USA

[14] Univ Hosp Virgen del Rocio, Seville, Spain

[15] Novartis OTM, E Hanover, NJ USA

[16] Novartis Pharmaceut, E Hanover, NJ USA

[17] NIBR Oncol, Basel, Switzerland

[18] Novartis OTM, Basel, Switzerland

[19] Univ Hosp Cologne, Cologne, Germany

来源：

CANCER RESEARCH | 2014年 / 74卷 / 19期

关键词：

D O I：

10.1158/1538-7445.AM2014-CT326

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT326

引用

页数：2

共 50 条

[41] Phase I study of pan-histone deacetylase inhibitor abexinostat in combination with cisplatin in patients with advanced solid tumors
Campone, M.
Isambert, N.
Sabatier, R.
Castanie, H.
Zanetta, S.
Sudey, I.
Cantero, F.
Pauly, J.
Leroux, E.
Malasse, S.
Goncalves, A.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : 189 - 189
[42] Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Nogova, Lucia
Sequist, Lecia V.
Garcia, Jose Manuel Perez
Andre, Fabrice
Delord, Jean-Pierre
Hidalgo, Manuel
Schellens, Jan H. M.
Cassier, Philippe A.
Camidge, D. Ross
Schuler, Martin
Vaishampayan, Ulka
Burris, Howard
Tian, G. Gary
Campone, Mario
Wainberg, Zev A.
Lim, Wan-Teck
LoRusso, Patricia
Shapiro, Geoffrey I.
Parker, Katie
Chen, Xueying
Choudhury, Somesh
Ringeisen, Francois
Graus-Porta, Diana
Porter, Dale
Isaacs, Randi
Buettner, Reinhard
Wolf, Juergen
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) : 157 - +
[43] A phase I open-label study of FGFR/VEGFR inhibitor FH-2001 in patients with advanced solid tumors
Song, Zhengbo
Hui, Ai-min
Wu, Zhuli
Liu, Huilong
Cheng, Xiangdong
CANCER RESEARCH, 2022, 82 (12)
[44] First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors.
Xu, Jian-Ming
Wang, Yan
Chen, Yu-ling
Jia, Ru
Shen, Lin
Wang, Jian
Sai, Yang
Qi, Chuan
Mu, Hua
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[45] Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors
Bahleda, Rastislav
Dienstmann, Rodrigo
Adamo, Barbara
Gazzah, Anas
Infante, Jeffrey R.
Zhong, Bob
Platero, Suso J.
Smit, Hans
Perera, Timothy
Stuyckens, Kim
Bussolari, Jacqueline
Poddareddigari, Vijay
Soria, Jean-Charles
Luo, Feng Roger
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[46] Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions
Makawita, Shalini
Kelley, Robin Kate
Roychowdhury, Sameek
Weiss, Karl Heinz
Abou-Alfa, Ghassan K.
Macarulla, Teresa
Sadeghi, Saeed
Waldschmidt, Dirk
Zhu, Andrew X.
Goyal, Lipika
Yong, Wei-Peng
Borbath, Ivan
El-Khoueiry, Anthony B.
Philip, Philip Agop
Moran, Susan
Ye, Yining
Soifer, Harris S.
Li, Gary
Berman, Craig
Javle, Milind M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[47] Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations.
Guo, Ye
Yuan, Chunwang
Ying, Jieer
Zhu, Xu
Luan, Guodong
Zhang, Bin
Zhao, Renbin
Li, Jin
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
Bono, P.
Massard, C.
Peltola, K.
Azaro, A.
Italiano, A.
Kristeleit, R. S.
Lassen, U. N.
Arkenau, H-T.
Hakulinen, P.
Garratt, C.
Ikonen, T.
Mustonen, M.
Rodon, J.
ANNALS OF ONCOLOGY, 2018, 29
[49] A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Voss, Martin H.
Hierro, Cinta
Heist, Rebecca S.
Cleary, James M.
Meric-Bernstam, Funda
Tabernero, Josep
Janku, Filip
Gandhi, Leena
Iafrate, A. John
Borger, Darrell R.
Ishii, Nobuya
Hu, Youyou
Kirpicheva, Yulia
Nicolas-Metral, Valerie
Pokorska-Bocci, Anna
Chessex, Anne Vaslin
Zanna, Claudio
Flaherty, Keith T.
Baselga, Jose
CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2699 - 2707
[50] Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors
Wu, Yi-Long
Zhang, Li
Trandafir, Lucia
Dong, Tuochuan
Duval, Vincent
Hazell, Katharine
Xu, Binghe
ANTICANCER RESEARCH, 2016, 36 (11) : 6185 - 6194

← 1 2 3 4 5 →